Skip to main content

Articles

Page 2 of 10

  1. Given the observed antitumor activity of immune-checkpoint-inhibitors in patients with mismatch-repair deficient (MSI-H) tumors, we hypothesized that deficiency in homologous-recombination-repair (HRR) can als...

    Authors: Miguel A. Villalona-Calero, John P. Diaz, Wenrui Duan, Zuanel Diaz, Eric D. Schroeder, Santiago Aparo, Troy Gatcliffe, Federico Albrecht, Siddhartha Venkatappa, Victor Guardiola, Sara Garrido, Muni Rubens, Fernando DeZarraga and Hao Vuong
    Citation: Biomarker Research 2022 10:39
  2. The claudin18.2 (CLDN18.2) protein, an isoform of claudin18, a member of the tight junction protein family, is a highly selective biomarker with limited expression in normal tissues and often abnormal expressi...

    Authors: Weijie Cao, Haizhou Xing, Yingmei Li, Wenliang Tian, Yongping Song, Zhongxing Jiang and Jifeng Yu
    Citation: Biomarker Research 2022 10:38
  3. Non-alcoholic fatty liver disease (NAFLD) is the commonest cause of chronic liver disease worldwide, being non-alcoholic steatohepatitis (NASH) its most clinically relevant form. Given the risks associated wit...

    Authors: Patricia Marañón, Carlos Ernesto Fernández-García, Stephania C. Isaza, Esther Rey, Rocío Gallego-Durán, Rocío Montero-Vallejo, Javier Rodríguez de Cía, Javier Ampuero, Manuel Romero-Gómez, Carmelo García-Monzón and Águeda González-Rodríguez
    Citation: Biomarker Research 2022 10:35
  4. In the last few decades, YAP has been shown to be critical in regulating tumor progression. YAP activity can be regulated by many kinase cascade pathways and proteins through phosphorylation and promotion of c...

    Authors: Yifan Cheng, Misha Mao and Yong Lu
    Citation: Biomarker Research 2022 10:34
  5. Immune checkpoint inhibitors have revolutionized cancer therapeutic paradigm and substantially improved the survival of patients with advanced malignancies. However, a significant limitation is the wide variab...

    Authors: Kamya Sankar, Jing Christine Ye, Zihai Li, Lei Zheng, Wenru Song and Siwen Hu-Lieskovan
    Citation: Biomarker Research 2022 10:32
  6. Exosomes, ranging in size from 30 to 150 nm as identified initially via electron microscopy in 1946, are one of the extracellular vesicles (EVs) produced by many cells and have been the subject of many studies...

    Authors: Ali Hazrati, Sara Soudi, Kosar Malekpour, Mohammad Mahmoudi, Arezou Rahimi, Seyed Mahmoud Hashemi and Rajender S. Varma
    Citation: Biomarker Research 2022 10:30
  7. Sestrin2 is a conserved antioxidant, metabolism regulator, and downstream of P53. Sestrin2 can suppress oxidative stress and inflammation, thereby preventing the development and progression of cancer. However,...

    Authors: Moein Ala
    Citation: Biomarker Research 2022 10:29
  8. Circular RNAs (circRNAs) are a type of recently discovered noncoding RNA. They exert their biological functions by competitively binding to microRNAs (miRNAs) as miRNA sponges, promoting gene transcription and...

    Authors: Qinfeng Zhou, Dacheng Xie, Rong Wang, Lianfang Liu, Yue Yu, Xinyi Tang, Yongxian Hu and Dawei Cui
    Citation: Biomarker Research 2022 10:28
  9. PD-L1 expression in non-small cell lung cancer (NSCLC) predicts response to immune checkpoint blockade, however is an imperfect biomarker given tumor heterogeneity, and the antigen presentation pathway requiri...

    Authors: Jennifer L. Schehr, Nan Sethakorn, Zachery D. Schultz, Camila I. Hernandez, Rory M. Bade, Diego Eyzaguirre, Anupama Singh, David J. Niles, Leslie Henderson, Jay W. Warrick, Scott M. Berry, Kaitlin E. Sundling, David J. Beebe, Ticiana A. Leal and Joshua M. Lang
    Citation: Biomarker Research 2022 10:26
  10. Kinase suppressor of Ras 2 (KSR2) is a regulator of MAPK signaling that is overactivated in most hepatocellular carcinoma (HCC). We sought to determine the role of KSR2 in HCC pathogenesis.

    Authors: Chao Gao, Si-wei Wang, Jia-cheng Lu, Xiao-qiang Chai, Yuan-cheng Li, Peng-fei Zhang, Xiao-yong Huang, Jia-bin Cai, Yi-min Zheng, Xiao-jun Guo, Guo-ming Shi, Ai-wu Ke and Jia Fan
    Citation: Biomarker Research 2022 10:25
  11. Chimeric antigen receptor T-cell (CAR-T) therapy is the result of combining genetic engineering-based cancer immunotherapy with adoptive cell therapy (ACT). CAR-T therapy has been successful in treating variou...

    Authors: Pouya Safarzadeh Kozani, Abdolhossein Naseri, Seyed Mohamad Javad Mirarefin, Faeze Salem, Mojtaba Nikbakht, Sahar Evazi Bakhshi and Pooria Safarzadeh Kozani
    Citation: Biomarker Research 2022 10:24
  12. Anti-programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) immunotherapy has dramatically changed the therapeutic landscape of inoperable non-small cell lung cancer (NSCLC), and has been included in firs...

    Authors: Lin Zhang, Weihao Lin, Fengwei Tan, Ning Li, Qi Xue, Shugeng Gao, Yibo Gao and Jie He
    Citation: Biomarker Research 2022 10:23
  13. Platinum-based chemotherapy was previously the first-choice treatment for lung cancer. The discovery of epidermal growth factor receptor (EGFR) gene mutations and the development of EGFR tyrosine kinase inhibi...

    Authors: Jiabao Hou, Hongle Li, Shuxiang Ma, Zhen He, Sen Yang, Lidan Hao, Hanqiong Zhou, Zhe Zhang, Jing Han, Li Wang and Qiming Wang
    Citation: Biomarker Research 2022 10:21
  14. Heterogeneous nuclear ribonucleoproteins C (HnRNP C) is part of the hnRNP family of RNA-binding proteins. The relationship between hnRNP C and cancers has been extensively studied, and dysregulation of hnRNP C...

    Authors: Liyi Mo, Lijuan Meng, Zhicheng Huang, Lan Yi, Nanyang Yang and Guoqing Li
    Citation: Biomarker Research 2022 10:19
  15. Neuroblastoma (NB) is a malignant tumor in young children that originates from the neural crest of the sympathetic nervous system. Generally, NB occurs in the adrenal glands, but it can also affect the nerve t...

    Authors: Shaohui Huang, Naying Gong, Jiangbin Li, Mingye Hong, Li Li, Ling Zhang and Hua Zhang
    Citation: Biomarker Research 2022 10:18
  16. Acute myeloid leukemia (AML) has the lowest survival rate among the leukemias. Targeting intracellular metabolism and energy production in leukemic cells can be a promising therapeutic strategy for AML. Recent...

    Authors: Yi Xu, Christopher Hino, David J. Baylink, Jeffrey Xiao, Mark E. Reeves, Jiang F. Zhong, Saied Mirshahidi and Huynh Cao
    Citation: Biomarker Research 2022 10:16

    The Correction to this article has been published in Biomarker Research 2022 10:33

  17. Epigenetics including DNA and RNA modifications have always been the hotspot field of life sciences in the post-genome era. Since the first mapping of N6-methyladenosine (m6A) and the discovery of its widespread ...

    Authors: Hang Song, Jianye Zhang, Bin Liu, Jing Xu, Biao Cai, Hai Yang, Julia Straube, Xiyong Yu and Teng Ma
    Citation: Biomarker Research 2022 10:15
  18. Adoptive cell therapy using patient-derived chimeric receptor antigen (CAR) T cells redirected against tumor cells has shown remarkable success in treating hematologic cancers. However, wider accessibility of ...

    Authors: Tiffany C. Y. Tang, Ning Xu, Robert Nordon, Michelle Haber, Kenneth Micklethwaite and Alla Dolnikov
    Citation: Biomarker Research 2022 10:14
  19. Adoptive cell therapy (ACT) is a particularly promising area of cancer immunotherapy, engineered T and NK cells that express chimeric antigen receptors (CAR) are being explored for treating hematopoietic malig...

    Authors: Zhiwu Jiang, Le Qin, Yuou Tang, Rui Liao, Jingxuan Shi, Bingjia He, Shanglin Li, Diwei Zheng, Yuanbin Cui, Qiting Wu, Youguo Long, Yao Yao, Zhihui Wei, Qilan Hong, Yi Wu, Yuanbang Mai…
    Citation: Biomarker Research 2022 10:13
  20. Natural killer (NK) cells are unique innate immune cells and manifest rapid and potent cytotoxicity for cancer immunotherapy and pathogen removal without the requirement of prior sensitization or recognition o...

    Authors: Leisheng Zhang, Yuan Meng, Xiaoming Feng and Zhongchao Han
    Citation: Biomarker Research 2022 10:12
  21. Multiple three-dimensional (3D) tumour organoid models assisted by multi-omics and Artificial Intelligence (AI) have contributed greatly to preclinical drug development and precision medicine. The intrinsic ab...

    Authors: Malia Alexandra Foo, Mingliang You, Shing Leng Chan, Gautam Sethi, Glenn K. Bonney, Wei-Peng Yong, Edward Kai-Hua Chow, Eliza Li Shan Fong, Lingzhi Wang and Boon-Cher Goh
    Citation: Biomarker Research 2022 10:10
  22. Immunotherapy has become the standard of care for non-small cell lung cancer (NSCLC), either in combination or monotherapy. However, there are still some patients who cannot benefit from it. Immunization strat...

    Authors: Yue Pan, Yucheng Fu, Yue Zeng, Xiaohan Liu, Yurong Peng, Chunhong Hu, Chao Deng, Zhenhua Qiu, Jian Zou, Yuxuan Liu and Fang Wu
    Citation: Biomarker Research 2022 10:9
  23. Family with sequence similarity 83 member A (FAM83A) presents oncogenic properties in several cancers including breast cancer. Recently, we reported FAM83A overexpression in normal breast tissues from women at...

    Authors: Natascia Marino, Rana German, Ram Podicheti, Pam Rockey, George E. Sandusky, Constance J. Temm, Harikrishna Nakshatri, Rebekah J. Addison, Bryce Selman, Sandra K. Althouse and Anna Maria V. Storniolo
    Citation: Biomarker Research 2022 10:8
  24. Patients with relapsed/refractory early T-cell precursor lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) respond poorly to traditional therapy and have dismal prognosis. CD7 is a promising therapeutic targets fo...

    Authors: Hai-ping Dai, Wei Cui, Qing-ya Cui, Wen-juan Zhu, Hui-min Meng, Min-qing Zhu, Xia-ming Zhu, Lin Yang, De-pei Wu and Xiao-wen Tang
    Citation: Biomarker Research 2022 10:6
  25. Inflammation is a process that protects organs against various potentially harmful stimuli and enables repair. Dysregulated inflammation, however, damages tissues and leads to disease, including cancer. Cancer...

    Authors: Jun Zhang and Nirmal Veeramachaneni
    Citation: Biomarker Research 2022 10:5
  26. The negatively charged aminophospholipid, phosphatidylserine (PtdSer), is located in the inner leaflet of the plasma membrane in normal cells, and may be exposed to the outer leaflet under some immune and bloo...

    Authors: Jiao Wang, Changxin Yu, Junyi Zhuang, Wenxin Qi, Jiawen Jiang, Xuanting Liu, Wanwei Zhao, Yiyang Cao, Hao Wu, Jingxuan Qi and Robert Chunhua Zhao
    Citation: Biomarker Research 2022 10:4
  27. Hepatocellular carcinoma (HCC) is one of the most common and lethal malignant tumors in the world. Therapeutic options for advanced HCC are limited. Systemic treatment, especially with conventional cytotoxic d...

    Authors: Huajun Zhang, Wuyang Zhang, Longying Jiang and Yongheng Chen
    Citation: Biomarker Research 2022 10:3
  28. Zinc finger proteins are transcription factors with the finger domain, which plays a significant role in gene regulation. As the largest family of transcription factors in the human genome, zinc finger (ZNF) p...

    Authors: Xinxin Li, Mengzhen Han, Hongwei Zhang, Furong Liu, Yonglong Pan, Jinghan Zhu, Zhibin Liao, Xiaoping Chen and Bixiang Zhang
    Citation: Biomarker Research 2022 10:2
  29. The increase in the number of therapeutic alternatives for both newly diagnosed and relapsed/refractory multiple myeloma (RRMM) patients has widened the clinical scenario, leading to a level of complexity that...

    Authors: José-Ángel Hernández-Rivas, Rafael Ríos-Tamayo, Cristina Encinas, Rafael Alonso and Juan-José Lahuerta
    Citation: Biomarker Research 2022 10:1
  30. Relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) has a very poor prognosis with a median overall survival of four to nine months. Achieving a complete molecular response is most often requ...

    Authors: Sophie Voruz, Sabine Blum, Laurence de Leval, Jacqueline Schoumans, Françoise Solly and Olivier Spertini
    Citation: Biomarker Research 2021 9:92
  31. Oral squamous cell carcinoma (OSCC) has poor survival rates. There is a pressing need to develop more precise risk assessment methods to tailor clinical treatment. Epigenome-wide association studies in OSCC ha...

    Authors: Chi T. Viet, Xinyu Zhang, Ke Xu, Gary Yu, Kesava Asam, Carissa M. Thomas, Nicholas F. Callahan, Coleen Doan, Paul C. Walker, Khanh Nguyen, Stephanie C. Kidd, Steve C. Lee, Anupama Grandhi, Clint T. Allen, Simon Young, James C. Melville…
    Citation: Biomarker Research 2021 9:90
  32. Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) is a rare, distinct subtype of T-ALL characterized by genomic instability, a dismal prognosis and refractoriness to standard chemotherapy. Since it...

    Authors: Francesco Tarantini, Cosimo Cumbo, Luisa Anelli, Antonella Zagaria, Giorgina Specchia, Pellegrino Musto and Francesco Albano
    Citation: Biomarker Research 2021 9:89
  33. Cancer is an intricate disease with inherent intra-tumor heterogeneity at the cellular level because of genetic changes and environmental differences. Cellular heterogeneity exists even within the same tumor t...

    Authors: Ruo Han Huang, Le Xin Wang, Jing He and Wen Gao
    Citation: Biomarker Research 2021 9:88
  34. By the emergence of recombinant DNA technology, many antibody fragments have been developed devoid of undesired properties of natural immunoglobulins. Among them, camelid heavy-chain variable domains (VHHs) an...

    Authors: Yasaman Asaadi, Fatemeh Fazlollahi Jouneghani, Sara Janani and Fatemeh Rahbarizadeh
    Citation: Biomarker Research 2021 9:87
  35. Early cancer diagnosis is a crucial element to improved treatment options and survival. Great research efforts have been made in the search for better performing cancer diagnostic biomarkers. However, the ques...

    Authors: Alien Balian and Frank J. Hernandez
    Citation: Biomarker Research 2021 9:86
  36. Histopathological examination (biopsy) is the “gold standard” for the diagnosis of colorectal cancer (CRC). However, biopsy is an invasive method, and due to the temporal and spatial heterogeneity of the tumor...

    Authors: Miao Jiang, Shuiling Jin, Jinming Han, Tong Li, Jianxiang Shi, Qian Zhong, Wen Li, Wenxue Tang, Qinqin Huang and Hong Zong
    Citation: Biomarker Research 2021 9:85
  37. Identifying and projecting the epidemiological burden of gastric cancer (GC) can optimize the control strategies, especially in high-burden areas.

    Authors: Xiaorong Yang, Tongchao Zhang, Hong Zhang, Shaowei Sang, Hui Chen and Xiuli Zuo
    Citation: Biomarker Research 2021 9:84
  38. Eosinophilia represents a group of diseases with heterogeneous pathobiology and clinical phenotypes. Among the alterations found in primary Eosinophilia, gene fusions involving PDGFRα, PDGFRβ, FGFR1 or JAK2 repre...

    Authors: Simone Romagnoli, Niccolò Bartalucci, Francesca Gesullo, Manjola Balliu, Stefania Bonifacio, Anair Graciela Lema Fernandez, Francesco Mannelli, Davide Bolognini, Elisabetta Pelo, Cristina Mecucci, Paola Guglielmelli and Alessandro Maria Vannucchi
    Citation: Biomarker Research 2021 9:83
  39. Lung cancer is one of the most common cancers in the world. Although medical treatment has made impressive progress in recent years, it is still one of the leading causes of cancer-related deaths in men and wo...

    Authors: Sikai Wu, Chengchu Zhu, Daolin Tang, Q. Ping Dou, Jianfei Shen and Xin Chen
    Citation: Biomarker Research 2021 9:82

Annual Journal Metrics